Julia Marie Eastland - 26 Nov 2023 Form 4 Insider Report for Harpoon Therapeutics, Inc.

Role
President and CEO, Director
Signature
/s/ Frank J. Lanza, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
26 Nov 2023
Net transactions value
$0
Form type
4
Filing time
28 Nov 2023, 16:30:30 UTC
Previous filing
31 May 2023
Next filing
09 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HARP Common Stock Award $0 +50,000 +1427% $0.000000 53,503 26 Nov 2023 Direct F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock, issuable upon the vesting and settlement of RSUs.
F2 25% of the RSUs will vest on each May 26th and November 26th of 2024 and 2025, subject to acceleration and vesting in full upon a Change in Control (as defined in the Issuer's 2019 Equity Incentive Plan) of the Issuer, and subject to the continuing employment of the Reporting Person on each vesting date.
F3 Includes 500 shares acquired under the Issuer's employee stock purchase plan on September 30, 2022, 750 shares acquired on March 31, 2023, and 2,253 shares acquired on September 29, 2023.
F4 Shares reflect 1:10 reverse stock split effective September 1, 2023.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney